Document:

exv10w12

 

IMAX CORPORATION

EXHIBIT 10.12

AMENDED EMPLOYMENT AGREEMENT

     This agreement amends the amended employment agreement (the “Agreement”) between Richard L.
Gelfond (the “Executive”) and IMAX Corporation (the “Company”) dated July 1, 1998, as amended, on
the same terms and conditions except as set out below:

	1.	 	Term. The term of the Agreement is extended until December 31, 2009.
	 
	2.	 	Cash Compensation. The Executive shall be entitled to be paid base salary at the rate of
$500,000 per year, plus a bonus of up to two times salary. Such bonus shall be at the
discretion of the Board of Directors and shall be based upon the success of the Company in
achieving the goals and objectives set by the Board after consultation with the Executive.
The Executive shall be considered for a bonus based upon performance during the years ending
December 31, 2008 and 2009. If the Executive’s employment is terminated without Cause prior
to the end of the term, the Executive shall be entitled to no less than a pro-rata portion of
his median bonus target (i.e. one times salary).
	 
	3.	 	Stock Appreciation Rights. The Executive is hereby granted 600,000 stock appreciation rights
(“SARS”) which shall entitle the Executive to receive in cash from the Company any increase in
the fair market value of the common shares of the Company from the fair market value thereof
on December 31, 2007 to the date of exercise of the SARS. The SARS shall vest according to
the following schedule: 150,000 on June 30, 2008, 150,000 on December 31, 2008, 150,000 on
June 30, 2009 and 150,000 on December 31, 2009. All SARS will have a 10-year term and, to the
extent applicable, shall be governed by the provisions of the Stock Option Plan of the Company
(“SOP”), including for greater certainty, the provisions relating to the calculation of the
fair market value of common shares of the Company; provided, however, that all
vested SARS shall remain exercisable for a period of three (3) years after either a
termination without Cause of the Executive or the non-renewal of this Agreement, and for one
(1) year after a resignation by the Executive. The vesting of all SARS shall be accelerated
upon a “change of control” as defined in the Agreement, and shall be governed, to the extent
applicable, by the provisions in the Agreement regarding change of control. At any time and
from time to time after vesting, but subject to the insider trading policy of the Company in
effect at that time which shall apply to the SARS as if they were securities covered thereby,
the Executive shall be entitled to exercise some or all of the vested SARS by delivering
notice of exercise in writing to the General Counsel of the Company. Within 10 business days
after receipt of such notice in writing, the Company shall pay to the Executive the amount by
which the fair market value of the common shares of the Company has increased from the fair
market value on December 31, 2007 to the fair market value on the date of such notice, net of
any applicable withholdings and any other amounts owing at that time by the Executive to the
Company. Notwithstanding anything to the contrary contained herein, the Company shall have
the right but not the obligation to cancel at any time all, or from time to time any part, of
the SARS, in any case upon notice in writing to the Executive and to replace the cancelled
SARS with stock options, provided that (i) such options or shares have no less favorable (to
the Executive) material terms and conditions as, and are in such number as are of equivalent
value to, the cancelled SARS, and (ii) the Company cannot replace cancelled SARS with stock
options if such options have a higher exercise price than the price of the common shares of
the Company on December 31, 2007.

 

	4.	 	The entering into this agreement shall not prejudice any rights or waive any
obligations under any other agreement between the Executive and the Company.

DATED as of December 31, 2007.

	 	 	 	 	 
	 	 	 
	 	“Richard L. Gelfond”
 	 
	 	Richard L. Gelfond 	 
	 	 	 
	 

	 	 	 	 	 
	 	IMAX CORPORATION

 	 
	 	Per:  	/s/ “Garth M. Girvan”
 	 
	 	 	Name:  	Garth M. Girvan 	 
	 	 	Title:  	Directorexv10w14

 

IMAX CORPORATION

EXHIBIT 10.14

FIRST AMENDING AGREEMENT

This Amendment to Employment Agreement dated as of December 31st, 2007 (the “Amending Agreement”)
is made between:

IMAX CORPORATION, a corporation incorporated under the laws of Canada (hereinafter referred to as
the “Company”),

and

GREG
FOSTER, of the City of Los Angeles in the State of California ( the “Executive”),

WHEREAS, the Company wishes to enter into this Amending Agreement to amend and extend the
Employment Agreement dated as of March 1, 2006 between the Company and the Executive (together, the
“Agreement”), whereunder the Executive provides services to the Company, and the Executive wishes
to so continue such engagement, as hereinafter set forth;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereto agree as follows:

1. Section 1.3 of the Agreement shall be deleted and replaced with the following:

“Section 1.3 Term of Employment. The Executive’s employment under this Agreement
commenced on the 19th day of March, 2001 (the “Commencement Date”) and shall terminate on the
earlier of (i) July 1, 2010, or (ii) the termination of the Executive’s employment pursuant to this
Agreement. The period commencing as of the Commencement Date and ending on July 1, 2010 or such
later date to which the term of the Executive’s employment under this Agreement shall have been
extended is hereinafter referred to as the “Employment Term.”

2. Section 2.2 of the Agreement shall be amended to add the following sentence at the end of the
first paragraph as follows:

“Notwithstanding the foregoing, in respect of each of the 2008 and 2009 fiscal years, the Executive
shall be paid a Minimum Bonus equal to US$ 425,000 per year.

3. Section 2.3.1 of the Agreement shall be deleted and replaced with the following:

“Section 2.3.1 Incentive Compensation. On the later of : (a) December 31st, 2007 and (b)
if, on December 31st, 2007, the Company has material information which has not been publicly
disclosed, the date which is fifteen (15) days after the date on which such information is publicly
disclosed, the Executive shall be granted 300,000 stock appreciation rights (“SARS”) which shall
entitle the Executive to receive in cash from the Company any increase in the fair market value of
the common shares of the Company from the fair market value thereof on December 31, 2007 to the
date of exercise of the SARS. 150,000 SARS shall vest on each of July 1, 2009 and July 1, 2010.
All SARS will have a 10-year term, commencing on the date of grant and, to the extent applicable,
the SARs shall be governed by the provisions of the Stock Option Plan of the Company (the “Plan”),
including for greater certainty, the provisions relating to the calculation of the fair market
value of common shares of the Company, resignation or termination; provided, however, that
to the extent any provisions of the Plan conflict with provisions of the Agreement, the provisions
of the Agreement shall apply. The vesting of all SARS shall be accelerated upon a “change of
control” as defined in the Plan and shall be governed, to the extent
applicable, by the provisions in the Agreement regarding change of control. At any time and from
time to time after vesting, but subject to the

 

 

insider trading policy of the Company in effect at
that time which shall apply to the SARS as if they were securities covered thereby, the Executive
shall be entitled to exercise some or all of the vested SARS by delivering notice of exercise in
writing to one of the Chief Executives of the Company. Within 10 business days after receipt of
such notice in writing, the Company shall pay to the Executive the amount by which the fair market
value of the common shares of the Company has increased from the fair market value on the date of
grant to the fair market value on the date of such notice, net of any applicable withholdings and
any other amounts owing at that time by the Executive to the Company. Notwithstanding anything to
the contrary contained herein, the Company shall have the right but not the obligation to cancel at
any time all, or from time to time any part, of the SARS, in any case upon notice in writing to the
Executive and to replace the cancelled SARS with a grant of stock options under the Plan (the
“Options”) provided that (i) such Options have no less favorable (to the Executive) material terms
and conditions as, and are in such number as are of equivalent value to, the cancelled SARS, and
(ii) the Company cannot replace cancelled SARs with stock options if such options have a higher
exercise price than the fair market value of the common shares of the Company on December 31st,
2007.

In addition, if there is a “Change of Control” of the Company (as defined in the Agreement) on or
before March 10, 2009, the Employee shall be paid an incentive bonus equal to the difference
between the price of the Common Shares upon such Change of Control and the price of the Common
Shares on March 10, 2006, multiplied by 50,000. Such incentive bonus shall be paid: (i) in a lump
sum in the event Employee is terminated Without Cause following such Change of Control, or (ii) in
three equal instalments on the third, fourth and fifth anniversaries of the grant date of the
Options.”

4. The Company agrees to hire a regular employee in the Human Resources Department who will be
dedicated to and principally located in the Company’s offices in Los Angeles.

5. The Company agrees that it will use its best efforts to ensure that the Executive is invited to
attend regularly scheduled meetings of the Board of Directors of the Company to the extent that the
Executive’s attendance is agreeable to the Board and is not inconsistent with good corporate
governance. The Executive understands and accepts that there may be meetings, or portions of
meetings, where his attendance would be inappropriate and that he will not attend on these
occasions.

Except as amended herein, all other terms of the Agreement shall remain in full force, unamended.

 

 

IN WITNESS WHEREOF, the Company and the Executive have duly executed and delivered this Amending
Agreement on this 31st day of December, 2007.

	 	 	 	 	 
	 	IMAX CORPORATION

 	 
	 	By:  	    “Bradley J. Wechsler”
 	 
	 	 	Name:  	Bradley J. Wechsler 	 
	 	 	Title:  	Co-Chief Executive Officer 	 
	 
	 	 	 
	 	By:  	                     “Richard L. Gelfond”
 	 
	 	 	Name:  	Richard L. Gelfond 	 
	 	 	Title:  	Co-Chief Executive Officer 	 
	 

	 	 	 	 	 
	SIGNED, SEALED AND DELIVERED

	 	EXECUTIVE:
	 	 
	in the presence of:
	 	 	 	 
	 
	“Jill Ferguson”

	 	“Greg Foster”	 	 
	 

	 	 	 	 
	Witness

	 	Greg Foster

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]